It began over a pint in a nondescript bar at an immunity and infectious disease conference in Lorne, a seaside town in Victoria, Australia. It was 2012 and Matt Cooper, a serial entrepreneur and a professor of chemical biology in the University of Queensland, was giving a talk to fellow scientists about antibiotics and superbugs. At the end of the talk he invited his audience to meet him in a nearby bar if they had any questions. In the audience was Luke O’Neill, a professor of biochemistry in Trinity College Dublin, who was also speaking at the conference. “Luke came…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .